CogniVue
Cognivue, Inc. is a privately held US neuroscience technology company that sells FDA-cleared, self-administered digital cognitive assessment devices (Clarity and Thrive) built on adaptive psychophysics to physicians, audiologists, and pharmacists for early detection of cognitive impairment.
- Company typePrivate
- Founded2009
- HeadquartersGatineau, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CogniVue does
Cognivue, Inc. is a privately held neuroscience technology company headquartered in Victor, New York, founded in 2009 and operating with 11-50 employees. The company develops FDA-cleared digital cognitive assessment devices built on a proprietary adaptive psychophysics platform, serving US-based healthcare providers (physicians, audiologists, and pharmacists) and patients seeking cognitive health monitoring. Its mission is to enable earlier detection of cognitive impairment so that modifiable risk factors can be addressed sooner.
The product portfolio centers on two hardware devices: Cognivue Clarity, a 10-minute self-administered assessment evaluating four cognitive domains (memory, executive function/attention, discrimination, visuospatial) plus two performance parameters, and Cognivue Thrive, a 5-minute abbreviated screening tool evaluating three cognitive domains (memory, visuospatial, executive function). Both use the proprietary CogniWheel single-point patient interface and capture over 130,000 data points per assessment. A patent-pending add-on module, the Cognivue Amyloid Risk Measure (CARM), applies machine learning to age plus three Clarity subtests to generate a four-point amyloid risk score for Alzheimer's risk stratification.
The business model is hardware sales of Clarity and Thrive to healthcare providers, supplemented by a per-use reimbursement pathway enabled by a distinct CPT procedural code created by the American Medical Association in 2019. Cognivue runs an enterprise field-sales motion across three verticals (physician practices, hearing healthcare, community pharmacy) with the EXCEL practice integration program, and a community-led motion anchored by participation in the FOCUS, Bio-Hermes-001, and Bio-Hermes-002 clinical studies alongside partners including Biogen, Eli Lilly, Roche, Sanofi, and the Global Alzheimer's Platform Foundation. The company is led by President and CEO Paul W. Estes and operates exclusively in the United States.
CogniVue firmographics
Firmographics- Name
- CogniVue
- Legal name
- Cognivue, Inc.
- Website
- https://cognivue.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cognivue, Inc. is a privately held US neuroscience technology company that sells FDA-cleared, self-administered digital cognitive assessment devices (Clarity and Thrive) built on adaptive psychophysics to physicians, audiologists, and pharmacists for early detection of cognitive impairment.
- Ownership category
- akta.pro rank
CogniVue industry classification
Industry- Product category
- Cognitive Assessment Medical Devices
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
Keywords
Where CogniVue is headquartered
LocationHeadquarters
- HQ city
- Gatineau
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
CogniVue business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Device Sales and Reimbursement: Cognivue Clarity and Thrive devices are sold to healthcare providers (physicians, audiologists, pharmacists). Insurance companies reimburse providers for two aspects: use of the Cognivue Clarity test itself (distinct CPT procedural code created in 2019) and time spent integration and interpretation of results into patient care including evaluation, clinical decision making, and treatment planning.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Per use | Insurance Reimbursement - Test Administration |
| Other | Per use | Insurance Reimbursement - Interpretation Services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
CogniVue product offering
Product offeringCore offering
CogniVue sells FDA-cleared, self-administered digital cognitive assessment hardware devices—Cognivue Clarity (10-minute, four-domain) and Cognivue Thrive (5-minute, three-domain)—to healthcare providers, using proprietary adaptive psychophysics that collects 130,000+ data points per test. The portfolio is augmented by the patent-pending Cognivue Amyloid Risk Measure (CARM) machine-learning algorithm and the patient-facing Cogniwell Lifestyle program for managing modifiable cognitive risk factors.
Product overview
CogniVue offers a digital cognitive assessment platform based on proprietary FDA-cleared technology using adaptive psychophysics. The portfolio includes two main FDA-cleared assessment devices: Cognivue Clarity (a 10-minute comprehensive cognitive assessment tool evaluating 4 domains plus performance parameters) and Cognivue Thrive (a 5-minute abbreviated screening tool evaluating 3 domains). Both devices collect 130,000+ data points per test and use the CogniWheel interface for patient interaction. An add-on feature called the Cognivue Amyloid Risk Measure (CARM) uses machine learning to predict amyloid presence for Alzheimer's risk stratification. CogniWell Lifestyle provides patient education on lifestyle factors affecting cognitive health.
Differentiator
Problem solved
Functional benefit
Brands
- Cognivue Clarity®: 10-minute self-administered computerized cognitive assessment device for physicians that evaluates 4 cognitive domains: memory, executive function/attention, discrimination, and visuospatial.
- Cognivue Thrive®
- Cogniwell®
Products and services
- Cognivue Clarity Device A 10-minute, self-administered computerized cognitive assessment device based on FDA-cleared technology, evaluating 4 cognitive domains (memory, executive function/attention, discrimination, and visuospatial) plus two performance parameters and collecting over 130,000 data points per patient via adaptive psychophysics. Sold to physician practices through enterprise field sales with EXCEL practice-integration support.
- Cognivue Thrive Device A 5-minute, self-administered computerized cognitive screening device using the same FDA-cleared adaptive psychophysics technology as Cognivue Clarity, evaluating 3 cognitive domains (memory, visuospatial, executive function) plus two performance parameters. Designed for hearing healthcare providers and community pharmacies to deliver quick cognitive screening in busy office and pharmacy workflows.
- Cogniwell Lifestyle Program A patient-facing lifestyle and education program that delivers evidence-based guidance on managing modifiable risk factors for cognitive health, covering mental fitness, social connections, exercise, nutrition, sleep, hearing health, vision care, and medication management. Aimed at patients who want to understand and proactively manage cognitive health.
Quantifiable outcome
- Cognivue is as effective as MoCA while demonstrating better test-retest reliability
- +5 more outcomes
Companies that use CogniVue
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
CogniVue technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
CogniVue partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- SanoficoreSanofi joined as newest partner in Bio-Hermes-002 observational study evaluating blood-based and digital biomarkers alongside imaging to improve prediction, detection, and diagnosis of Alzheimer's disease. Sanofi will analyze additional biomarkers to augment the study's existing database.
- Global Alzheimer's Platform Foundation (GAP)coreStrategic partnership for Bio-Hermes-002 longitudinal study investigating digital and blood-based biomarkers in relationship to tau and amyloid PET imaging. Cognivue Clarity is one of the digital biomarkers being evaluated. Study builds on Bio-Hermes-001 findings. Cognivue joins existing GAP partners including Biogen and other pharmaceutical/diagnostic companies.
- DigiCARE RealizedcoreStrategic partnership to improve routine brain care across healthcare systems, focusing on earlier detection of Alzheimer's disease and related dementias (ADRD). Combines two transformative cognitive assessment technologies following landmark FDA approval of Leqembi.
- The Kutcher Clinic for Sports NeurologyminorFirst-of-its-kind large-scale concussion study conducted by The Kutcher Clinic evaluating and refining how concussions are identified and treated using evidence-based diagnostic inputs including Cognivue technology.
- Avant InstituteminorPartnership for grant program - one of twelve recipients of inaugural Global Davos Alzheimer's Collaborative Grant Program for Healthcare System Preparedness. Launching innovative early detection program for Alzheimer's in pharmacies nationwide.
- BiogencoreExisting GAP partner in Bio-Hermes-001 and Bio-Hermes-002 studies. Biogen is one of the strategic partners collaborating on the Bio-Hermes clinical trial program.
- Eli LillycoreExisting GAP partner in Bio-Hermes studies. Part of the pharmaceutical and diagnostics partner network.
- RochecoreExisting GAP partner in Bio-Hermes studies. Part of the pharmaceutical and diagnostics partner network.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
CogniVue competitors and assessment
Company assessmentDirect peers
- Altoida: Digital cognitive assessment using smartphone-based AR/AI tasks to detect early signs of cognitive impairment and MCI/AD risk; competes for the same early-detection positioning with a non-hardware delivery model.
- Cambridge Cognition: Digital cognitive assessment company whose CANTAB platform directly competes with Cognivue Clarity/Thrive; both companies are co-participants in the Bio-Hermes-002 study evaluating digital biomarkers against imaging.
- Linus Health: Digital cognitive assessment platform (DCTclock and related tools) targeting early detection of cognitive impairment and Alzheimer's; co-participant with Cognivue in Bio-Hermes-002.
- BrainCheck: Tablet- and web-based cognitive assessment platform used by clinicians for cognitive impairment screening; targets the same primary-care and specialty physician channel as Cognivue Clarity.
- CNS Vital Signs: Computerized neurocognitive assessment battery widely used by clinicians and researchers; competes in the same computerized cognitive testing category as Cognivue Clarity.
- Cogstate: Commercial provider of computerized cognitive tests used in clinical trials and healthcare; overlapping product category with Cognivue's adaptive testing, including FDA-cleared elements and pharma trial deployment.
- Neurotrack: Digital cognitive health company offering computerized assessments for early detection of memory impairment and Alzheimer's; addresses overlapping primary-care and consumer use cases as Cognivue.
Others
- MoCA Test: The Montreal Cognitive Assessment paper test against which Cognivue benchmarks itself; represents the incumbent cognitive screening standard that Cognivue aims to displace digitally.
- Quanterix (Lucent Diagnostics): Blood-based biomarker developer (Simoa platform) co-participant in Bio-Hermes-002 alongside Cognivue; represents an alternative (blood-based) modality for early AD detection that may complement or compete with CARM.
- Global Alzheimer's Platform (GAP) Foundation: Non-profit clinical trial infrastructure that convenes Cognivue, Biogen, Sanofi, Roche, Eli Lilly, and digital biomarker peers in the Bio-Hermes studies; ecosystem partner rather than a competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
CogniVue social profiles
Digital presenceCogniVue financial estimates
Financial estimateRevenue estimate
Valuation estimate
CogniVue leadership team
Management profileNumber of profiles
Profiles7 records
CogniVue funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CogniVue M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CogniVue
What does CogniVue do?
CogniVue sells FDA-cleared, self-administered digital cognitive assessment hardware devices—Cognivue Clarity (10-minute, four-domain) and Cognivue Thrive (5-minute, three-domain)—to healthcare providers, using proprietary adaptive psychophysics that collects 130,000+ data points per test. The portfolio is augmented by the patent-pending Cognivue Amyloid Risk Measure (CARM) machine-learning algorithm and the patient-facing Cogniwell Lifestyle program for managing modifiable cognitive risk factors.
Is CogniVue a public or private company?
CogniVue is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CogniVue founded?
CogniVue was founded in 2009. It employs 11 to 50 people.
Where is CogniVue based?
CogniVue is headquartered in Gatineau, Canada, in the North America region.
How does CogniVue make money?
One revenue line is on record: device Sales and Reimbursement.
Who are CogniVue's main competitors?
Direct peers on record are Altoida, Cambridge Cognition, Linus Health, BrainCheck, CNS Vital Signs, Cogstate and Neurotrack. Others are MoCA Test, Quanterix (Lucent Diagnostics) and Global Alzheimer's Platform (GAP) Foundation.
Does CogniVue have an API?
No public API is recorded for CogniVue.
What industry is CogniVue in?
CogniVue's product category is Cognitive Assessment Medical Devices. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 5132 and its SIC code is 7372.